Previous studies have shown that the inhibitory effect of betulinic acid (BA) on specificity protein 1 (Sp1) expression is involved in the prevention of cancer progression, but the mechanism of this effect remains to be delineated. In this study, we determined that BA treatment in HeLa cells increased the sumoylation of Sp1 by inhibiting sentrin-specific protease 1 expression. The subsequent recruitment of E3 ubiquitin-protein ligase RING finger protein 4 resulted in ubiquitin-mediated degradation in a 26S-proteosome-dependent pathway. In addition, both BA treatment and mithramycin A (MMA) treatment inhibited lung tumor growth and down-regulated Sp1 protein expression in Kras G12D -induced lung cancers of bitransgenic mice. In gene expression profiles of Kras G12D -induced lung cancers in bitransgenic mice with and without Sp1 inhibition, 542 genes were affected by MMA treatment. One of the gene products, cyclin A2, which was involved in the S and G 2 /M phase transition during cell cycle progression, was investigated in detail because its expression was regulated by Sp1. The down-regulation of cyclin A2 by BA treatment resulted in decreased retinoblastoma protein phosphorylation and cell cycle G 2 /M arrest. The BA-mediated cellular Sp1 degradation and antitumor effect were also confirmed in a xenograft mouse model by using H1299 cells. The knockdown of Sp1 in lung cancer cells attenuated the tumor-suppressive effect of BA. Taken together, the results of this study clarify the mechanism of BA-mediated Sp1 degradation and identify a pivotal role for Sp1 in the BA-induced repression of lung cancer growth.
Introduction
Lung cancer is the most prevalent type of cancer and the leading cause of cancer-related death. Although chemotherapy can relieve symptoms and improve survival, most patients with lung cancer die of either progressive local disease or metastatic disease. Clinical pathologists divide lung cancers into two broad categories: small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLCs are further divided into three major types: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLCs constitute 85% of all lung cancers, with adenocarcinoma accounting for 30 to 50% of all cases of lung cancer (Langer et al., 2010) . Because the 5-year survival rate of patients with lung cancer is low (Goldstraw et al., 2007) , the development of more effective cancer therapies with fewer side effects is an important goal.
Betulinic acid (BA), a pentacyclic triterpenoid isolated from Betula alba, is a candidate for cancer therapy that has been shown to exhibit an antitumor effect without cytotoxicity (Zuco et al., 2002; Alakurtti et al., 2006) . The administration of BA reduced the tumor burden of established melanoma and prostate cancer xenografts in nude mice (Pisha et al., 1995; Chintharlapalli et al., 2007) . In particular, BA induces tumor cell death by inducing mitochondria-mediated apoptosis (Mullauer et al., 2010) . In addition, BA inhibits prostate cancer tumor growth by degrading a transcription factor, specificity protein 1 (Sp1), which ultimately inhibits angiogenesis (Chintharlapalli et al., 2007) . However, the effect of BA on cell cycle progression, the mechanism of BAinduced Sp1 degradation, and the relevance of Sp1 degradation to the antitumor effect of BA in other cancers, including lung cancer, have not been elucidated. Sp1 regulates several cellular functions and influences tumor growth by regulating the transcription of genes involved in proliferation, including cyclin D1, c-Jun, and c-Myc (Wierstra, 2008) . The level of Sp1 increases in various types of cancers , and deletion of Sp1 reduces tumor growth in nude mice implanted with gastric cancer cells (Jiang et al., 2004) . Sp1 is also involved in the nicotine-induced growth of lung cancer cells (Sun et al., 2009) . Although the Sp1 inhibitor mithramycin A (MMA), which inhibits the binding of Sp1 to GC-rich sequences in gene promoters, including the Sp1 gene, has an antitumor effect, its cytotoxicity in normal tissues is very high (Guichard et al., 2006; Yang et al., 2010; Tian et al., 2011) . Because the down-regulation of Sp1 is an effective therapeutic strategy in antitumorigenesis, it would be worthwhile to develop or discover new cancer therapy drugs that target Sp1 with less cytotoxicity.
Cell cycle progression is tightly controlled by the cyclin/ cyclin-dependent kinase complex. Cell cycle deregulation caused by overexpression of cyclins, such as cyclin D1, occurs in various types of cancers (Musgrove et al., 2011) . In particular, Sp1 has been shown to regulate the transcriptional expression of cyclins D1 and E, both of which are involved in the G 1 /S phase transition (Hilton et al., 2005; Kim et al., 2006) . In addition to DNA synthesis in the S phase, cyclin A2 also regulates the G 2 /M phase transition by promoting nuclear envelope breakdown, nuclear accumulation of cyclin B1, and activation of the M phase promoting complex (Gong et al., 2007; Bendris et al., 2011) . Despite the essential role of cyclin A2 in cell proliferation, few studies have addressed the importance of cyclin A2 in the therapeutic effect of antitumor drugs.
In this study, we show that BA inhibited lung tumor growth in a xenograft model and in bitransgenic mice with spontaneously developed lung tumors induced by Kras under the control of doxycycline. In lung adenocarcinoma cells, BA induced apoptosis and cell cycle arrest at the G 2 /M phase. At the molecular level, BA decreased the level of Sp1 by repressing SENP1 and thereby inducing Sp1 sumoylation, which resulted in ubiquitin-mediated protein degradation of Sp1 in a proteasome-dependent manner. Moreover, the BA-mediated decrease in Sp1 blocked the cyclin A2/Rb signaling cascade, causing cell cycle arrest at G 2 /M. Furthermore, Sp1 knockdown attenuated BA-induced cell cycle arrest and apoptosis. Taken together, our results support the hypothesis that attenuation of the cellular Sp1 level is a strategy to control lung tumorigenesis.
Materials and Methods
Cell Lines. The human lung cancer cell lines, A549 and H1299, and the human cervical cancer cell line, HeLa, were purchased from American Type Culture Collection (Manassas, VA). These cell lines were cultured in DMEM (Invitrogen, Carlsbad, CA) containing 10% FBS, 100 mg/ml streptomycin sulfate, and 100 U/ml penicillin G sodium at 37°C and 5% CO 2 .
Chemicals. (Promega, Madison, WI) . H1299 cells were infected with lentiviruses at 5 MOI multiplicity of infection, which is the ratio of virus particles to infected cells, for 3 days to achieve effective Sp1 knockdown. Subsequently, H1299 cells, which were infected with scramble-or Sp1 shRNA-expressed lentiviruses for 3 days, were treated with the indicated dose of BA for additional 36 h.
Collection of Clinically Resected Lung Adenocarcinoma Specimens. Clinical specimens were obtained from 36 patients with stage I lung adenocarcinoma, who underwent surgery at the Department of Surgery of National Cheng Kung University Hospital. The process of human specimen collection was approved by the Clinical Research Ethics Committee at National Cheng Kung University Medical Center.
Generation of Bitransgenic Mice (Scgb1a1-rtTA/TetOKras G12D ). Scgb1a1-rtTA and TetO-Kras G12D transgenic mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and cared for at the National Laboratory Animal Center in Taiwan. The expression of rtTA protein was driven by the promoter of Scgb1a1 in type II epithelial cells in lungs of Scgb1a1-rtTA transgenic mice. After mating, Kras G12D expression was driven by the doxycyclineactivated rtTA-bound tetracycline-responsive promoter element (TRE; TetO) in lungs from bitransgenic mice characterized by PCR genotyping. Kras G12D expression was induced by drinking water containing 0.5 g/l doxycycline (Sigma-Aldrich) at the age of 2 months. The control group drank reverse osmosis water. BA and MMA were administered by intraperitoneal injection. After treatment for the indicated period, whole lung tissue containing lung tumors was homogenized and prepared as whole tissue protein for Western blotting. For histological analysis, whole lung tissue containing lung tumors was fixed in 10% formaldehyde.
Immunohistochemistry. Lungs from bitransgenic mice and clinically resected specimens were fixed in 10% formaldehyde for 24 h and embedded in paraffin. Histological sections with 5 m were stained with hematoxylin-eosin (HE) after dewaxation in xylene and rehydration in decreasing concentrations of ethanol. For immunostaining, hydrogen peroxide (0.3% in PBS) was used to block endogenous peroxidase for 30 min at room temperature. Subsequently, sections were incubated in the appropriate primary antibody diluted in 2% BSA in PBS for 2 h at room temperature. Finally, the immunoreactivity was visualized with a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) and photographed under an Olympus BX-51 microscope (Olympus, Melville, NY). For the evaluation of Sp1 expression in clinically resected human lung adenocarcinomas, more than 30% of cells stained with Sp1 in the individual histological slide were considered as positive staining.
RT-PCR. Total RNA was prepared using TRIzol (Invitrogen) according to the manufacturer's instructions. Three micrograms of RNA were used for RT with SuperScript III (Invitrogen). The primers for PCR were as follows: human Sp1, F, 5Ј-ACTAGTGTCCGGGTTCGCTT-GCCT-3Ј and R, 5Ј-GGCGCCAAAGTTGTGTGGCTGTGA-3Ј; human cyclin A2, F, 5Ј-GGTACCCCATTTCAATAGTC-3Ј and R, 5Ј-GAGCTCAAAT-TGTTGGTTCA-3Ј; mouse cyclin A2, F, 5Ј-GAACGTTAATGAAG TACCTGAC-3Ј and R, 5Ј-CAGGGTCTCATTCTGTAGTTTA-3Ј; and glyceraldehyde-3-phosphate dehydrogenase, F, 5Ј-CCATCACCATCTTCCAG-GAG-3Ј and R, 5Ј-CCTGCTTCACCACCTTCTTG-3Ј. PCR products were analyzed by ethidium bromide-containing agarose gel electrophoresis.
Xenograft Study. The animal experiment was approved by the Institutional Animal Care and Use Committee at National Cheng Kung University. Female athymic BALB/c nude mice (8 weeks old) were purchased from National Laboratory Animal Center in Taiwan. H1299 cells (1 ϫ 10 6 cells) were suspended in 100 l of PBS and implanted into the back of athymic nude mice. DMSO (for control) or BA (10 mg/kg) was injected intraperitoneally into mice every 3 days. The width (a) and length (b) of the tumor were measured by calipers for the evaluation of tumor volume according to the formula V ϭ ba 2 /2 (Conway et al., 2000) . Flow Cytometry for Cell Cycle Analysis. The cells were trypsinized and washed with 4°C PBS. After fixation with 4°C 75% ethanol for 24 h, the cells were treated with 10 g/ml RNase A (QIAGEN, Valencia, CA) and stained with 50 g/ml PI (SigmaAldrich) for 30 min at 37°C. To analyze cell distribution in the cell cycle, PI-stained cells were analyzed by a flow cytometer (FACSCalibur; BD Biosciences, San Jose, CA). Data were analyzed by WinMDI software.
Microarray Analysis. Total RNA was extracted using TRIzol from lungs of control mice, doxycycline-treated bitransgenic mice, and doxycycline-treated bitransgenic mice injected intraperitoneally with MMA. Microarray analysis was performed by Phalanx Biotech Group (Hsinchu, Taiwan). Microarray data were analyzed by using Ingenuity software.
Proliferation Assay. After plating cells (1 ϫ 10 5 ) in the 6-cm dish for 24 h, the medium was changed to DMEM-10% FBS containing DMSO for the control or different doses of BA for the indicated time. To examine cell proliferation, cells were trypsinized and counted by hemacytometer after treatment with BA. Each experiment was duplicated and repeated three times.
Construction of CCNA2 Promoters for Reporter Assay. For construction, genomic DNA of HeLa cells was prepared. CCNA2 promoter (Ϫ1000/ϩ50) was produced by PCR using primers: F, 5Ј-GGTACCGGTTTTAAAATGGCATAC-3Ј and R, 5Ј-AGATCTGGAGCG-GCGGCTGTTCTT-3Ј; deletion form (Ϫ1000/Ϫ151), F, 5Ј-GGTACCG-GTTTTAAAATGGCATAC-3Ј and R, 5Ј-AGATCTGAGGTAGGATTTA GGGCC-3Ј; and deletion form containing putative Sp1-binding sites (Ϫ150/ϩ50), F, 5Ј-GGTACCTCCCCGCCCCGCGCAGGC-3Ј and R, 5Ј-AG-ATCTGGAGCGGCGGCTGTTCTT-3Ј. After purification and amplification, plasmids were ligated to pGL2 vector using restriction enzymes, KpnI and BglII (New England Biolabs, Ipswich, MA).
Mutagenesis. The CCNA2 promoter (Ϫ1000/ϩ50) plasmid was used as the template for mutagenesis of Sp1-binding sites. Primers for mutations of Ϫ89/Ϫ88C to Ϫ89/Ϫ88A: F, 5Ј-CTCCCTCCTGC-CCCGAACCTGCTCAGTTTCCT-3Ј and R, 5Ј-AGGAAACTGAGCAG-GTTCGGGGCAGGAGGGAG-3Ј; and for Ϫ144/Ϫ143C to Ϫ144/ Ϫ143A: F, 5Ј-TCCTACCTCTCCCCGAACCGCGCAGGCGTTTT-3Ј and R, 5Ј-AAAACGCCTGCGCGGTTCGGGGAGAGGTAGGAϪ3Ј. Mutagenesis was performed by PCR using plaque-forming unit DNA polymerase (Agilent Technologies, Santa Clara, CA).
Transfection and Luciferase Assay. After cells were plated in an appropriate number in six-well plates for 24 h, transfection was achieved by incubating cells with Opti-MEM (Invitrogen) containing 2 g of the pGL2-vector or pGL2-SENP1 or pGL2-CCNA2 promoter plasmid and 2 l of lipofectamine (Invitrogen) at 37°C and 5% CO 2 for 6 h. Subsequently, Opti-MEM was replaced with DMEM-10% FBS and incubated for an additional 36 h in the presence of DMSO or BA with GFP-or GFP-Sp1-expressed adenoviruses. Luciferase activity in cell lysates was determined by luminometer (LB9506; Berthold Technologies, Bad Wildbad, Germany).
Immunoprecipitation. Whole-cell lysates (500 g), which were prepared by using radioimmune precipitation assay (RIPA) buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.1% Nonidet P-40, 10 g/ml leupeptin, and 10 g/ml aprotinin), were immunoprecipitated with 1 g of anti-Sp1 (Millipore Corporation, Billerica, MA), 1 g of anti-RNF4 (Sigma-Aldrich), or 2 g of anti-ubiquitin antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in modified RIPA buffer for 2 h at 4°C. Protein A agarose beads (30 ml; Millipore Corporation) were mixed with immunoprecipitated lysates and incubated for additional 1 h at 4°C. After four washes with RIPA buffer, beads were collected by centrifugation at 5000 rpm for 3 min at 4°C and eluted by 1.5ϫ sample buffer for electrophoresis and subsequent immunoblotting with the indicated antibody.
Western Blotting. Whole-cell lysates were collected for electrophoresis, transfer to polyvinylidene difluoride membrane (GE Healthcare, Baie d'Urfe, QC, Canada), and immunoblotting with antibodies against Sp1, Kras (ProteinTech Group, Chicago, IL), RNF4, caspase 3 (Cell Signaling Technology, Beverly, MA), cyclin A2 (ProteinTech Group), SENP1 (Epitomics Inc., Burlingame, CA), poly-(ADP-ribose)polymerase (PARP) (Epitomics), phospho-Rb (Ser807; Cell Signaling Technology), caspase 3 (Cell Signaling Technology), Rb (ProteinTech Group), regulatory particle ATPase 6 (Rpt6) (Biomol International L.P., Butler Pike, PA), Flag (Sigma-Aldrich), tubulin (Sigma-Aldrich), and ␤-actin (Sigma).
MTT Assay. After infection with lentiviruses expressing the indicated shRNA for 3 days, cells were seeded in a 96-well plate (5000 cells/well) and treated with BA for an additional 36 h. Then cell viability was determined by using an MTT assay kit according to the manufacturer's instruction (Biovision Inc., Milpitas, CA).
Chromatin Immunoprecipitation Assay. After cross-linking with 1% formaldehyde (Merck, Darmstadt, Germany) for 10 min at room temperature, cells (1 ϫ 10 8 ) were washed with ice-cold PBS three times, and whole-cell extracts were prepared with lysis buffer. The cellular DNA fragment (500 base pairs) was prepared by sonication. For immunoprecipitation, salmon sperm DNA-blocked cell lysate was incubated with 2 g of anti-Sp1 antibody or IgG at 4°C for 16 h with rotation. After incubation with 30 l of protein A agarose beads at 4°C for additional 2 h, beads were washed three times with high salt buffer (20 mM Tris-HCl, 500 mM NaCl, 2 mM EDTA, and 0.5% Nonidet-40) and another three times with low salt buffer (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, and 0.01% SDS). Subsequently, proteins binding to beads were eluted by 500 l of TE buffer (10 mM Tris-HCl, pH 7.5, and 1 mM EDTA) containing 1% SDS, and cross-links were reversed at 65°C for 16 h. After protein digestion by 0.5 mg/ml proteinase K at 50°C for 2 h, DNA was extracted by phenol-chloroform and precipitated by icecold absolute alcohol. The purified DNA was analyzed by PCR using the primer for CCNA2 promoter (Ϫ188/ϩ1): F, 5Ј-TTAAAATAATCG-GAAGCG-3Ј and R, 5Ј-ACCAATGAAAGCGCTCGC-3Ј.
Statistical Analysis. Student's t test was used to compare the difference between DMSO-and BA-treated groups. Two-way analysis of variance was used to compare the growth curve of tumors from DMSO-and BA-treated athymic nude mice.
Results

BA Decreases the Sp1 Level in Lung Adenocarcinoma by Modulating Its Post-Translational Modification.
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prostate cancer by degrading Sp1 protein, but it is still not clear how Sp1 is degraded (Chintharlapalli et al., 2007) . First, we checked the transcriptional activity of Sp1 by detecting Sp1 mRNA (Fig. 1A) . No significant difference in the Sp1 mRNA levels was observed in cancer cells with and without BA treatment (30 M) for 36 h. Therefore, Sp1 protein stability was studied under BA treatment (Fig. 1B) . BA treatment significantly reduced the half-life of Sp1 in H1299 cells, suggesting that BA induces Sp1 protein instability. The ubiquitination of Sp1 was then measured in the absence or presence of BA. Ubiquitination of Sp1 was observed after BA treatment [ Fig. 1C(a) ]. Our previous studies revealed that sumoylation of Sp1 leads to Sp1 degradation, but phosphorylation of Sp1 increases its stability . The sumoylation and phosphorylation of Sp1 were then studied under BA treatment. No significant difference in the phosphorylation of Sp1 (Thr739) was observed with and without BA treatment (data not shown). On the other hand, sumoylation increased with BA treatment [ Fig. 1C(b) ]. To investigate whether the sumoylation of Sp1 was specific, Flag-SENP1 was overexpressed in cells, and Sp1 sumoylation was assessed. As indicated in [ Fig. 1C(c) ], Sp1 sumoylation decreased with Flag-SENP1 overexpression, indicating that the signal in [Fig. 1C(b) ] is Sp1 sumoylation. To study whether endogenous SENP1 was affected by BA treatment, we examined the effect of BA on SENP1 expression. BA inhibited the transcriptional activity [ Fig. 1D(a) Fig. 1E(b) ]. These results suggest that BA increases the level of SUMO-Sp1 by repressing SENP1 expression, leading to degradation of Sp1 in a 26S-proteosome-dependent pathway in lung cancer cells.
A Decrease in Sp1 Level Is Important for the BAMediated Anti-Lung Cancer Effect. As indicated in Fig.  1 , we determined the mechanism of Sp1 degradation by BA treatment in lung cancer cells. We then addressed the relationship between Sp1 degradation and BA-mediated inhibition of lung cancer growth. First, the cell morphology of lung cancer cells, H1299 and A549, was studied upon treatment with various doses of BA. The cell morphology and cell number of lung cancer cells were not affected by 10 and 20 M BA, but an effect was observed with 30 and 40 M BA ( Fig. 2A) . Next, the cell lysates were used to evaluate the Sp1 level (Fig. 2B) . There was no difference in the Sp1 level after the 10 or 20 M BA treatment, but there was an obvious decrease in the Sp1 level after 30 or 40 M BA treatment, compared with the Sp1 level in controls (Fig. 2B) . Taken together, these results indicating a good correlation between cell growth inhibition and Sp1 down-regulation with BA treatment suggest that Sp1 might be important for the anti-lung cancer effect of BA.
We then addressed the relationship between the Sp1 level and lung tumor formation and the influence of BA treatment on this relationship (Fig. 3A),) . First, to clarify the clinical significance of Sp1 expression in tumorigenesis, Sp1 protein expression was detected in specimens from patients with lung cancer by immunohistochemical staining (Fig. 3A ; Table  1 ). Among 36 patients with stage I lung adenocarcinomas, 29 patients (81%) exhibited high Sp1 expression, whereas only 7 (19%) exhibited low Sp1 expression. This result suggests that Sp1 accumulation is involved in human lung tumor growth. Although BA has been shown to be effective against prostate cancer (Chintharlapalli et al., 2007) , its effect on other cancers, especially lung cancer, was not clear. Therefore, we evaluated the therapeutic effects of BA on lung cancer in a xenograft mouse model and in a bitransgenic mouse model. Treatment of animals with BA attenuated both tumor size and tumor weight in SCID mice implanted with H1299 cells (Fig. 3B) . To confirm whether BA inhibits spontaneous lung tumor growth in vivo, we used a bitransgenic mouse model (Scgb1a1-rtTA/TetO-Kras G12D ). These mice spontaneously develop lung tumors through doxycycline-induced expression of mutant Kras (Fisher et al., 2001) . As shown in Fig. 3C(a) , the bitransgenic mice that received doxycycline alone for 5 months developed lung tumors, whereas BA treatment (20 mg/kg, once every 3 days) in the 4th and 5th months of doxycycline treatment prevented tumor development. This result indicates that BA inhibits the spontaneous lung tumor growth in vivo. Moreover, immunohistochemical staining [ Fig. 3C(b) ] and Western blotting [ Fig. 3C(c) ] showed that BA treatment blocked up-regulation of Sp1, but not that of Kras, and up-regulated caspase 3 [ Fig.  3C(c) ]. These results suggest that BA blocks lung tumor growth by inducing apoptosis.
To address more specifically the role of Sp1 in BA-mediated anti-lung tumorigenesis, Sp1 was knocked down by shRNA in lung cancer cells (Fig. 4A),) . First, the cell number was counted, and viability was assayed after BA treatment with or without Sp1 knockdown. The data indicated that cells were more resistant to BA after Sp1 knockdown (Fig. 4, A and B). Cell death was then assayed using flow cytometry. As indicated in Fig. 4C, 16 .33 and 70.05% of cells were found in the sub-G 1 fraction after treatment with 30 and 50 M BA, respectively. In the Sp1 knockdown condition treated with 30 and 50 M BA, 7.34 and 27.62% of cells were found in the sub-G 1 fraction, respectively. Finally, cleaved PARP and active caspase 3 were investigated in cells with or without Sp1 knockdown (Fig. 4D) . Cleaved PARP and active caspase 3 were induced by various doses of BA in cells without Sp1 knockdown but not in the Sp1 knockdown condition. This result suggests that Sp1 is required for BA-mediated cell apoptosis.
Sp1-Mediated Genes Are Involved in the BA-Induced Repression of Lung Cancer in Kras G12D -Driven Lung Tumors. In addition to BA, we also studied the effect of another Sp1 inhibitor, MMA, on Kras G12D -driven lung tumors in the doxycycline-induced transgenic mouse model. In accordance with the results from BA treatment, treatment with MMA (0.5 mg/kg, once per week) during the last 2 months of a 5-month doxycycline treatment clearly prevented both tumor formation [ Fig. 3C(a) ] and Sp1 up-regulation in lung tumors, as analyzed by immunohistochemical analysis (Fig. 5A) . The effects of treatment with BA and MMA, which induce degradation of Sp1 protein and inhibit binding of Sp1 to promoters, respectively, suggest that Sp1 down-regulation is involved in BA-and MMA-attenuated lung tumor formation in the bitransgenic mouse model.
To further address the functional role of Sp1 in lung cancer formation, total RNA was extracted from MMA-treated lung tissues containing tumors, and the gene expression profile was investigated by microarray analysis (Fig. 5) . MMA treatment repressed 542 genes in Kras G12D -driven lung cancer mice (Supplemental Figs. S2 and S3 ). Functional grouping analysis using Ingenuity software showed that 68 of these genes were related to cell proliferation. Of these 68, 40 genes have been reported to be involved in proliferation ( Fig. 5B ; Supplemental Fig. S3 ; Supplemental Table 1 ). We also used samples obtained from BA-treated lung cancer cells and BAor MMA-treated mice bearing Kras-driven lung tumors to determine the expression level of important genes involved in cell proliferation, such as CCNA2, EGR1, CTSZ, VAV1, TAC-STD2, TPX2, and CD9. The results from microarray analysis indicated that the mRNA expression of these important genes was inhibited by BA treatment in Kras-driven lung tumors and in H1299 cells ( Fig. 6A),; Supplemental Fig. S4 ).
BA Decreases Cyclin A2 Expression by Suppressing Sp1 Expression in Lung Cancer Formation. Because cyclin A2 is essential for cell cycle progression and tumorigenesis (Yasmeen et al., 2003) , we next examined cyclin A2 expression in Kras G12D -driven lung tumors from doxycyclineinduced transgenic mice to confirm the results from the microarray analysis. As shown in Fig. 6 , A and B, treatment of Kras G12D -induced lung cancer mice with either MMA or BA inhibited cyclin A2 expression at the mRNA and protein levels in the lung tissue containing tumors. In addition, lung tumor xenografts from BA-treated nude mice exhibited lower levels of cyclin A2 and Sp1 than those from DMSO-treated nude mice (Fig. 6C) .
To determine whether the cyclin A2 gene (CCNA2) is regulated by Sp1 at the transcriptional level, we searched for with BA in the last 1 month and 2 months during the doxycycline treatment period. Lungs were exercised, and immunohistochemical analyses were performed by using antibodies against Sp1 and Kras. Representative images of HE and immunohistochemical stains are shown. C(c), lungs from bitransgenic mice were used to prepare tissue lysates for Western blot analyses by using antibodies against Sp1, Kras, caspase 3, and ␤-actin Betulinic Acid Attenuates Sp1-Regulated CCNA2 in Lung Cancer 
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Sp1-binding sites in the CCNA2 promoter by using bioinformatics software (TFSEARCH; Tsukuba, Japan). We found two Sp1-binding sites located at Ϫ149/Ϫ141 (score 95.9) and Ϫ94/Ϫ86 (score 94.5) ahead of the transcription start site (ϩ1). Chromatin immunoprecipitation assays revealed that Sp1 bound to the CCNA2 promoter (Ϫ188/ϩ1) [ Fig. 6D(a) ]. In addition, the reporter assay indicated that GFP-Sp1 overexpression significantly enhanced CCNA2 transcriptional activity in H1299 cells, whereas BA treatment significantly attenuated the effect of Sp1 [ Fig. 6D(b) ]. Subsequently, to establish whether Sp1-binding sites are important for CCNA2 transcription, the transcriptional activity driven by CCNA2 promoter (Ϫ150/ϩ50) with Sp1-binding sites or by CCNA2 promoter (Ϫ1000/Ϫ151) without Sp1-binding sites was analyzed. As shown in Fig. 6D(c) , GFP-Sp1 overexpression significantly enhanced the activity of the promoter Ϫ150/ϩ50 and not that of the promoter Ϫ1000/Ϫ151. Moreover, the transcriptional activity driven by promoter Ϫ1000/ Ϫ151 was clearly lower than that driven by promoter Ϫ150/ ϩ50. Furthermore, mutations of Sp1-binding sites significantly blocked GFP-Sp1-enhanced CCNA2 transcription [ Fig. 6D(d) ]. The expression of GFP or GFP-Sp1 in H1299 cells analyzed by a reporter assay was confirmed by Western blot analysis (Supplemental Fig. S5 , B, C, and D). We also showed that Sp1 overexpression significantly increased the protein level of cyclin A2 in H1299 cells (Supplemental Fig. S5A ). These results indicate that Sp1 directly regulates CCNA2 promoter activity. In addition to the inhibition of CCNA2 transcription by BA, the CCNA2 mRNA level was also decreased in BA-treated H1299 and A549 lung cancer cell lines (Fig. 6E) . A previous study showed that cyclin A2 is important for both G 1 to S and G 2 to M transitions of the cell cycle (Yasmeen et al., 2003) . Because cyclin A2 is essential for Rb phosphorylation, the phosphorylation of Rb in BA-treated lung adenocarcinoma cells was studied. As shown in Fig. 7A ), BA treatment simultaneously attenuated CCNA2 expression and the phospho-Rb signal. Furthermore, Rb phosphorylation was also studied in MMA-and BA-treated Kras G12D -driven lung tumor samples (Fig. 7B) . The phosphorylated Rb signal was induced in Kras G12D -driven lung tumors, but the signal was abolished after MMA or BA treatment. Finally, apoptosis or cell cycle arrest at the G 2 /M phase in BA-treated cells was assessed by flow cytometry analysis. In A549 cells, the proportions of cells in the sub-G 1 and G 2 /M fractions were 1.3 and 16.3%, respectively, whereas the proportions of cells in the sub-G 1 and G 2 /M fractions increased to 17.03 and 22.91%, respectively, after treatment with 30 M BA (Fig.  7C, top panel) . In H1299 cells, treatment with 30 M BA increased the proportions of cells in the sub-G 1 and G 2 /M populations from 2.5 to 10.75% and from 13.12 to 23.48%, respectively (Fig. 7C, bottom panel) . These results suggest that BA-mediated Sp1 down-regulation blocks the cyclin A2/Rb signaling cascade, resulting in cell cycle arrest at the G 2 /M phase.
On the basis of these findings, we propose a model to explain the mechanism underlying BA-induced Sp1 degradation to inhibit lung cancer growth (Fig. 8) . In lung tumor cells, BA induces sumoylation by decreasing SENP1 expression. The subsequent ubiquitination of Sp1 protein results in Sp1 degradation in a proteasome-dependent manner. The decrease in Sp1 reduces the level of cyclin A2 by attenuating CCNA2 transcription. Decreased Rb phosphorylation then causes cell cycle arrest at the G 2 /M phase and, finally, apoptosis.
Discussion
In this study, we found that BA decreased SENP1 levels, which increased Sp1 sumoylation and the recruitment of the Sp1 E3 ligase, RNF4, to degrade Sp1. We also observed that -driven lung tumorigenesis. Bitransgenic mice were treated with doxycycline (Dox) with MMA (0.5 mg/kg, once per week) in the last 2 months during 5 months of treatment with doxycycline. A, lungs were harvested and prepared for histological analysis. Representative images of lung sections for HE staining and for immunohistochemical analysis were stained using antibodies against Sp1 and Kras. B, a heat map of 68 genes related to proliferation was created using the GenePattern Web site.
Betulinic Acid Attenuates Sp1-Regulated CCNA2 in Lung Cancer Fig. 6 . Effect of BA on Sp1-regulated cyclin A2 expression in lung adenocarcinomas. A, RNA from lungs of bitransgenic mice treated with MMA (a) or BA (b) was analyzed by RT-PCR using primers for CCNA2. Data are representative of eight independent experiments and are presented as the mean Ϯ S.E.M. ‫,ء(‬ P Ͻ 0.05, determined by Student's t test). Dox, doxycycline; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. B(a) and B(b), protein was analyzed by Western blotting with anti-cyclin A2 antibody. Data are representative of eight independent experiments and are presented as the mean Ϯ S.E.M. ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, determined by Student's t test). C, lysates prepared from H1299 cell-xenografted tumors in athymic nude mice treated as indicated were prepared as lysates for Western blotting with antibodies against Sp1, cyclin A2, and ␤-actin. Data are representative of six independent experiments and are presented as the mean Ϯ S.E.M. ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, determined by Student's t test). DS, DMSO. D(a), binding of Sp1 to the CCNA2 promoter (Ϫ188/ϩ1) was analyzed by a chromatin immunoprecipitation (IP) assay. D(b), H1299 cells, which were transfected with 2 g of pGL2 or pGL2-CCNA2 promoter plasmid and cultured in the presence or absence of BA (30 M) for 36 h with GFP-or GFP-Sp1-expressed adenoviruses, were harvested for preparation of whole-cell lysates for luciferase activity assays. Data are representative of three the Sp1 level is important for the BA-mediated anti-lung cancer effect.
BA is a naturally occurring pentacyclic triterpene that exhibits a variety of biological activities, including potent antiviral and anticancer effects (Alakurtti et al., 2006) . A previous study indicated that the anticancer activity is contributed by its ability to trigger mitochondrial membrane permeabilization (Fulda, 2009) . The anticancer activity of BA has been studied in a wide variety of cancer cell lines, primarily in tumor samples and xenograft mouse models (Fulda, 2008) of melanoma, neuroectodermal tumors, leukemia, and head and neck, colon, breast, hepatocellular, lung, prostate, renal cell, ovarian, and cervical cancers (Pisha et al., 1995; Fulda et al., 1997 Fulda et al., , 1999 Zuco et al., 2002; Thurnher et al., 2003; Ehrhardt et al., 2004) . Whereas most studies addressed the antitumor activity of BA in cell lines, some were performed in nude mice. In an in vivo model of metastatic melanoma, the addition of BA augmented vincristine suppression of experimental lung metastasis of melanoma cells (Sawada et al., 2004) . Past studies on the effect of BA on lung cancer focused on cancer cell lines such as H460 cells (Zuco et al., 2002) without in vivo studies to address the role of BA in lung tumorigenesis. In this study, we not only used xenograft experiments to examine the effect of BA on lung cancer formation but also used a bitransgenic lung tumor mouse model, in which conditional expression of Kras G12D promotes spontaneous tumor development, to study the effect of BA on lung cancer formation. The data shown in Fig.  3C indicate that BA significantly represses lung tumor growth. In the bitransgenic lung tumor mouse model, the Sp1 level decreased, and caspase 3 was activated by BA treatment (Fig. 3C) . Taken together, these in vivo results support the hypothesis that BA inhibits lung cancer growth by influencing Sp1 level, thereby triggering apoptosis.
We also investigated whether the antitumor effect of BA was dependent on Sp1 expression. As shown in Fig. 4 , we demonstrated that Sp1 knockdown decreased the sensitivity of lung cancer cells to BA treatment. The effects of BA on the growth parameters obtained from a proliferation assay, cell cycle analysis, apoptosis assay, and proapoptotic protein expression were significantly attenuated in Sp1 knockdown cells. As indicated in Fig. 4D , BA reduced Sp1 levels efficiently in cells containing a high level of Sp1, but it did not further decrease Sp1 when Sp1 was knocked down. The underlying mechanisms by which BA only affects Sp1 in cells with a high level of Sp1 requires further study. We also found that a decrease in the Sp1 level was not enough to induce cancer cell death because cell apoptosis was not induced when we used shRNA to knockdown Sp1. Therefore, BA not only induces Sp1 degradation but also modulates other factor(s) in cancer cells to induce cell apoptosis.
Sp1 regulates the expression of genes related to several cellular functions, and its expression is essential for tumor growth (Wierstra, 2008) . Previous studies showed that Sp1 accumulates in most cancer cell types . Both transcriptional activity and protein stability contribute to the increased Sp1 level observed during tumorigenesis . Recent studies found that post-translational modification of Sp1 modulates Sp1 stability. Sp1 is stabilized by phosphorylation at Thr739 but is destabilized by sumoylation Wang et al., 2008) . Our recent finding indicates that the interplay between phosphorylation and sumoylation modulates the ubiquitination of Sp1 by recruiting the E3 ubiquitin ligase RNF4 (Wang et al., 2011) . Although a previous study indicated that BA inhibits Sp1 in LNCaP cells, the mechanism of this inhibition remained unclear (Chintharlapalli et al., 2007) . Herein, we clarified the mechanism by which BA induces Sp1 degradation: BA increased the sumoylation of Sp1 by decreasing the level of SENP1 (Fig. 1) . We also determined the effect of BA on the phosphorylation of Sp1 at Thr739 and found no significant effect (data not shown), but we did observe that the interaction between Sp1 and RNF4 increased with BA treatment [ Fig. 1E(a) ]. This finding implies that sumoylation of Sp1 increases RNF4 recruitment, which leads to Sp1 degradation in a ubiquitination-dependent, 26S-proteasome-dependent pathway.
In addition to revealing the mechanism by which BA treatment leads to Sp1 degradation, we also elucidated, in detail, the molecular mechanism by which BA-mediated Sp1 degradation inhibits lung tumor growth. In particular, we analyzed the change in global gene expression induced by the Sp1 inhibitor MMA in lung tissue containing few lung tumors (Fig. 5) . A number of genes contain one or more Sp1-binding elements within their promoter regions, implying that Sp1 could regulate these genes. This observation, in turn, implies that the enhancement of Sp1-mediated gene expression facilitates lung tumor formation. Because of the difficulty of confirming the roles of all Sp1-regulated genes identified by the microarray analysis, we examined proliferation-related genes that were potentially regulated by Sp1 to elucidate the contributions of Sp1-regulated genes to tumor growth. Among the 68 Sp1-regulated genes related to proliferation, seven genes, namely, Aldh3a1, Arg1, Cd9, Ptx3, Tacstd2, Tpx2 , and Vav1, have been reported to be overexpressed in lung tumors or to be biomarkers for the diagnosis of lung cancer (Shimada et al., 2005; Ma et al., 2006; Moreb et al., 2008; Lazer et al., 2009; Rotondo et al., 2009; Kohmo et al., 2010; Diamandis et al., 2011) . In addition, Ctsz, Il18, Il4ra, Lcn2, Ntrk3, and Ros1 have been shown to be involved in tumor growth and cancer pathogenesis (Wood et al., 2006; Todaro et al., 2008; Berger et al., 2010; Sevenich et al., 2010; Rovina et al., 2011) . The microarray data suggest that several genes involved in tumorigenesis are regulated by Sp1. We examined the gene expression of several important genes, such as CCNA2, EGR1, CTSZ, VAV1, TACSTD2, TPX2, and independent experiments, each of which was performed in triplicate. Data are presented as the mean Ϯ S.E.M. ‫,ءءء(‬ P Ͻ 0.001, determined by Student's t test). D(c), H1299 cells, which were transfected with 2 g of pGL2, pGL2-CCNA2 (Ϫ1000/ϩ50), pGL2-CCNA2 (Ϫ1000/Ϫ151), or pGL2-CCNA2 (Ϫ150/ϩ50) promoter plasmid and cultured for 36 h with GFP-or GFP-Sp1-expressed adenoviruses, were harvested for preparation of whole-cell lysates for luciferase activity assays. P values determined by Student's t test are indicated. NS, not significant. D(d), H1299 cells, which were transfected with 2 g of pGL2, pGL2-CCNA2 (Ϫ1000/ϩ50), mutant pGL2-CCNA2 (C Ϫ144, Ϫ143 A) or mutant pGL2-CCNA2 (C Ϫ89, Ϫ88 A) promoter plasmid and cultured for 36 h with GFP-or GFP-Sp1-expressed adenoviruses, were harvested for preparation of whole-cell lysates for luciferase activity assays. P values determined by Student's t test are indicated. E(a) and E(b), RNA from cells treated with DMSO (control) or BA for 36 h was extracted for RT-PCR. Data are representative of three independent experiments and are presented as the mean Ϯ S.E.M. ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, determined by Student's t test). CD2, and found that they were down-regulated by BA treatment. Previous studies have shown that the strong expression of cyclin A2, which mediates cell cycle transitions from the G 1 to S and G 2 to M phase, predicts poor prognosis for patients with several types of cancer (Yasmeen et al., 2003; Chan et al., 2010) . Because of the critical role of cyclin A2 in cell cycle progression, it should be targeted by tumor therapy. Herein, we showed that the levels of Sp1 and cyclin A2 significantly increased in lung tumors, whereas BA blocked both of these increases and cyclin A2-mediated Rb phosphorylation. Furthermore, cyclin A2 expression was regulated transcriptionally by Sp1 through the 2 Sp1-binding sites (Ϫ149/Ϫ141 and Ϫ94/Ϫ86). Deletion of the Sp1-binding sites dramatically attenuated CCNA2 transcriptional activity, indicating that Sp1 was absolutely required for CCNA2 gene expression. These results also suggest that BA inhibits lung tumor growth by blocking the Sp1-mediated cyclin A2/Rb signaling cascade, which is required for cell cycle progression. It has been reported that BA induces tumor cell death by inducing apoptosis via a mitochondria-dependent pathway (Mullauer et al., 2010) . We showed that in addition to apoptosis, BA induces cell cycle arrest at G 2 by decreasing the level of cyclin A2. Previous studies have also reported that down-regulation of cyclin A2 results in growth inhibition and G 2 arrest in several cancer cell lines (Badie et al., 2000; Chan et al., 2010) . On the basis of these findings, we speculate that cyclin A2 down-regulation-mediated G 2 /M arrest is a prerequisite for subsequent apoptosis in BA-treated tumor cells. Previous studies showed that BA induces cell apoptosis through the CD95/TNF-related apoptosis-inducing ligand pathway (Fulda et al., 1997) . In this study, we elucidated a new pathway by which BA can induce cell growth arrest. Therefore, these two pathways might be involved in BAinduced apoptosis in parallel. In addition, although regulation of CCNA2 by Sp1 in BA-induced tumor suppression is important, other Sp1-regulated genes might also be involved in the inhibitory effect of BA on lung cancer formation.
In this study, we determined the mechanism of BA-mediated Sp1 degradation and reported a novel BA-induced apoptotic pathway. These findings provide supportive evidence for treating lung tumors by inhibiting Sp1. 
